Indication:
Novel Drug/New Approvals for 2016-New
(For more salient details please refer the Drug)
No. Drug Name Active Ingred. Apprvl Date FDA Approved use on approved date
M- Manufacturer D- Distributor
1.ZEPATIER Embasir Jan 2016
2.BRIVACT Brivaracetam Feb 2016
3.ANTHIM Obiltoximab Mar 2016
4.TALTZ Ixelizumab Mar 2016
5.CINQUAIR Resilzumab Mar 2016
6.DEFITELIO Defibrotide Mar 2016
7.VENCLEXTA Venetoclax April 2016
8.NUPLAZID Pimavanserin April 2016
9.TECENTRIQ Atezolizumab May 2016
10. ZINBRYTA Daclizumab May 2016
11. OCLAVIA Obeeticholic May 2016
12. AXUMIN Fluciclovine F-118 May 2016
13.NETSPOT Gallium June 2016
14.EPCLUSA Sofosbuvir June 2016
15.XILDRA Lifitegrast July 2016
16. ALDYXIN Luxisenatide July 2016
17. EXONDYS 51 Eteplilsen Sept 2016
18.LATTUVO Olaratumab Oct 2016
19.ZINPLAVA Bezlotoxumab Oct 2016
20.EROCRISA Crisaborole Dec 2016